153 related articles for article (PubMed ID: 36777499)
1. Temozolomide combined with ipilimumab plus nivolumab enhances T cell killing of MGMT-expressing, MSS colorectal cancer cells.
Gonzalez Z; Carlsen L; El-Deiry WS
Am J Cancer Res; 2023; 13(1):216-226. PubMed ID: 36777499
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O
Morano F; Raimondi A; Pagani F; Lonardi S; Salvatore L; Cremolini C; Murgioni S; Randon G; Palermo F; Antonuzzo L; Pella N; Racca P; Prisciandaro M; Niger M; Corti F; Bergamo F; Zaniboni A; Ratti M; Palazzo M; Cagnazzo C; Calegari MA; Marmorino F; Capone I; Conca E; Busico A; Brich S; Tamborini E; Perrone F; Di Maio M; Milione M; Di Bartolomeo M; de Braud F; Pietrantonio F
J Clin Oncol; 2022 May; 40(14):1562-1573. PubMed ID: 35258987
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143.
Omuro A; Reardon DA; Sampson JH; Baehring J; Sahebjam S; Cloughesy TF; Chalamandaris AG; Potter V; Butowski N; Lim M
Neurooncol Adv; 2022; 4(1):vdac025. PubMed ID: 35402913
[TBL] [Abstract][Full Text] [Related]
4. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
5. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
6. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
[TBL] [Abstract][Full Text] [Related]
7. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
Gupta SK; Kizilbash SH; Carlson BL; Mladek AC; Boakye-Agyeman F; Bakken KK; Pokorny JL; Schroeder MA; Decker PA; Cen L; Eckel-Passow JE; Sarkar G; Ballman KV; Reid JM; Jenkins RB; Verhaak RG; Sulman EP; Kitange GJ; Sarkaria JN
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26615020
[TBL] [Abstract][Full Text] [Related]
8. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
[TBL] [Abstract][Full Text] [Related]
9. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
[TBL] [Abstract][Full Text] [Related]
10. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
[TBL] [Abstract][Full Text] [Related]
11. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET
Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889
[TBL] [Abstract][Full Text] [Related]
12. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
[TBL] [Abstract][Full Text] [Related]
14. Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers.
Svrcek M; Buhard O; Colas C; Coulet F; Dumont S; Massaoudi I; Lamri A; Hamelin R; Cosnes J; Oliveira C; Seruca R; Gaub MP; Legrain M; Collura A; Lascols O; Tiret E; Fléjou JF; Duval A
Gut; 2010 Nov; 59(11):1516-26. PubMed ID: 20947886
[TBL] [Abstract][Full Text] [Related]
15. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer.
Cecchini M; Zhang JY; Wei W; Sklar J; Lacy J; Zhong M; Kong Y; Zhao H; DiPalermo J; Devine L; Stein SM; Kortmansky J; Johung KL; Bindra RS; LoRusso P; Schalper KA
Cancer Res Commun; 2023 Jun; 3(6):1132-1139. PubMed ID: 37387791
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide Induces the Acquisition of Invasive Phenotype by O6-Methylguanine-DNA Methyltransferase (MGMT)
Kochanowski P; Catapano J; Pudełek M; Wróbel T; Madeja Z; Ryszawy D; Czyż J
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923767
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibition suppresses the emergence of temozolomide resistance in a model system.
Yuan AL; Meode M; Tan M; Maxwell L; Bering EA; Pedersen H; Willms J; Liao J; Black S; Cairncross JG; Blough MD
J Neurooncol; 2020 Jul; 148(3):463-472. PubMed ID: 32562246
[TBL] [Abstract][Full Text] [Related]
18. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
19. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy in Hepatogastroenterology - update 2022: efficacy and immune-related adverse events].
Krimmel L; Quante M; Bengsch B
Dtsch Med Wochenschr; 2023 Mar; 148(6):294-300. PubMed ID: 36878227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
